Please log in to determine if you are eligible to purchase PT Programs.

Since antimicrobial resistance has increased steadily and varies by geographic location and patient population, the availability of up-to-date cumulative antimicrobial susceptibility is crucial. These data are also essential to monitor emerging trends in resistance at the local level to support clinical decision-making, evaluate infection control interventions, inform and participate in antimicrobial stewardship efforts, optimize microbiology susceptibility testing and reporting, and guide Pharmacy and Therapeutics Committee formulary decisions.

Annual Enrollment in this study assists laboratories in meeting the CAP Laboratory Accreditation Program Checklist statement MIC.21946, Cumulative Susceptability Data, and The Joint Commission Antimicrobial Stewardship Standard, MM 09.01.01.


This study will assist the laboratory and health care facility with antimicrobial stewardship by ongoing comparison and trending of cumulative susceptibility rates for common microorganisms within a facility over time and between participating facilities.

Data Collection

New participants will provide cumulative susceptibility data for each year from 2019 to 2021, while continuing participants will provide data for 2021. Susceptibility rate data including the number of isolates tested will be collected for select microorganisms including Enterobacter cloacae complex, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, methicillin-susceptible Staphylococcus aureus (MSSA) and methicillin-resistant Staphylococcus aureus (MRSA), and Enterococcus species. Continuing participants may additionally provide 2019-2020 data for MSSA and MRSA. Standardized data collection methods will be used by all participants in accordance with recommended guidelines.

Performance Indicator

  • Trend of antimicrobial susceptibility rates from 2018 to 2021 for specific microorganisms.

Shipping Schedule

A Mailing: December 6, 2021

Additional Information

This is a one-time study conducted in the first quarter.

Q-PROBES qualify for Self-Reported Training Opportunities to be used for fulfilling requirements for certification maintenance by agencies such as the American Society for Clinical Pathology (ASCP). Please verify with your certifying agency to determine your education requirements.

For Comprehensive Collection of Tools, see Quality Management Tools.

Select Q-PROBES and Q-TRACKS studies to support your quality improvement initiatives.
Anatomic Pathology
Clinical Pathology
Turnaround Time
Patient Safety
Transfusion Medicine
Chemistry/ Hematology
Customer Satisfaction
Antimicrobial Susceptibility Testing: Monitoring and Trend Analysis (QP211)
Laboratory Staffing Rarios (QP222)
Technical Competency Assessment of Peripheral Blood Smears (QPC10/QPC25)
Technical Competency Assessment of Gram Stains (QPD10/QPD25)
Patient Identification Accuracy (QT1)
Blood Culture Contamination (QT2)
Laboratory Specimen Acceptability (QT3)
In-Date Blood Product Wastage (QT4)
Gynecologic Cytology Outcomes: Biopsy Correlation Performance (QT5)
Satisfaction with Outpatient Specimen Collection (QT7)
Stat Test Turnaround Time Outliers (QT8)
Critical Values Reporting (QT10)
Troponin Turnaround Times (QT15)
Corrected Results (QT16)
Outpatient Order Entry Errors (QT17)

*The CAP requires accredited laboratories to have a quality management plan that covers all areas of the laboratory and includes benchmarking key measures of laboratory performance (GEN.13806, GEN.20316, COM.04000). The Joint Commission requires accredited hospitals to regularly collect and analyze performance data (PI.01.01.01, PI.02.01.01). CLIA requires laboratories to monitor, assess, and correct problems identified in preanalytic, analytic, and postanalytic systems (§493.1249, §493.1289, §493.1299).